External broker reports(aggregated public sources), Nirmal Bang

Nirmal Bang

External broker reports(aggregated public sources)

A Relationship Beyond Broking

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering them a range of financial products and services, including equities, derivatives, commodities, currency derivatives, mutual funds, IPOs, insurance, depository services and PMS.

Nirmal Bang is drawn from a diversity of professional backgrounds, and blend of experience, skill and dedication is shared with its clients. Nirmal Bang emphasizes adequate, thorough research local and world-wide developments, balancing these with the astute discovery of intrinsic values, synergies and growth. The aim is simply to help the investors to maximize their returns.

Equity Bottom-Up

<div><ul><li>4QFY22 Earnings Highlights: SS<span style="font-size: var(--content-font-size);">L reported revenue of Rs3,837mn, up 6% YoY and 7.2% QoQ.</span></li></ul><div><div><div><div><ul><li>Formulations business reported sales at Rs2,563mn, up 2.3% YoY and 0.3% QoQ.</li></ul><div><div><div><div><ul><li>Europe formulations business reported sales at Rs1,034mn, down 7.1% YoY and 1.8% QoQ.</li></ul></div></div></div></div></div></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

4QFY22 Earnings Highlights: SSL reported revenue of Rs3,837mn, up 6% YoY and 7.2% QoQ.Formulations business reported sales at Rs2,563mn, up 2.3% YoY and 0.3% QoQ.Europe formulations business reported sales at Rs1,034mn, down 7.1% YoY and 1.8% QoQ.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Sequent Scientific - Recovery in API Business; Gross Margin Remains Below FY21

India

Viyash Scientific is an integrated pharmaceutical company with a global presence, specializing in animal and human health. The company manufactures Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage formulations, along with providing analytical services. It has manufacturing facilities in India, Turkey, Brazil, Spain, and Germany, serving customers in over 100 countries. The company was incorporated in 1985 and is headquartered in Hyderabad, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Viyash Scientific (VIYASH IN)

Sequent Scientific - Recovery in API Business; Gross Margin Remains Below FY21

Sequent Scientific’s (SSL) 4QFY22 revenue at Rs3,837mn was broadly in line with our estimate. However, EBITDA and net profit declined by 8% QoQ and...

Nirmal Bang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)